Clinical trials: Airflow Obstruction, Chronic
Chronic Obstructive Pulmonary Disease
Feel Breathe, Restriction Device Ventilatory Nasal (COPD)
FEELBREATHE®, a nasal ventilatory restriction device, used during an exercise test in treadmill produces changes on breathing efficiency in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- BreatheCOPD (NCT01695265)
- Testing
- Exercie oronasal breathing (ONB), Exercie nasal breathing through the FB
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- University of Cadiz
COPD (Chronic Obstructive Pulmonary Disease)
Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm
Under-diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is prevalent, with an estimated 75% of adults suffering from COPD in the US, without clinical recognition.
- Trial name
- COPD (NCT07223749)
- Where
- United States
- Volunteers
- 425 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)
The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00891462
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 561 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Biomarkers in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide and is characterized by fixed airflow obstruction.
- Trial name
- NCT01145300
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Leiden University Medical Center
Pulmonary Disease, Chronic Obstructive
Sputum Colour Charts to Guide Antibiotic Self-treatment of Acute Exacerbation of COPD (Colour COPD)
The primary objective of this study is to determine if a sputum colour chart can aid patient self-management of COPD exacerbations, such that use of the chart is non-inferior to usual care with respect to hospital admissions.
- Trial name
- NCT04705233
- Testing
- sputum colour chart
- Where
- United Kingdom
- Volunteers
- 2,954 people
- Sponsor
- University of Birmingham
COPD
Complexity of the Airflow in COPD
Recently, there has been a growing interest in the study of nonlinear dynamics as a methodology for complementary analysis to characterize the respiratory pattern. These methods are well established in studies of heart rate.
- Trial name
- NCT01888705
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Rio de Janeiro State University
Chronic Obstructive Pulmonary Disease
Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients
To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.
- Trial name
- NCT00832611
- Testing
- Arteriovenous Fistula (ROX AC1)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- ROX Medical, Inc.
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies.
- Trial name
- NCT01437397
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 222 sites in United States, Australia and 2 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
Chronic Obstructive Lung Disease, Airflow Obstruction
Screening for Obstructive Respiratory Disorders in the General Population During the "Mai Poumon 2026" Prevention Campaign: Prevalence and Impact on the Care Pathway
Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD…
- Trial name
- Mai Poumons 26 (NCT07575880)
- Testing
- Spirometry
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier de la côte Basque
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall Inhaler and formoterol 12 μg via the Foradil®…
- Trial name
- NCT01551888
- Testing
- Aclidinium/formoterol 400/12μg, Formoterol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders
The objectives of this study were to evaluate the effect of a one-year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function, incidence and severity of exacerbations in patients with chronic obstructive…
- Trial name
- NCT00274014
- Testing
- Tiotropium
- Where
- 55 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD Exacerbation
Effects of High Flow Nasal Cannula on Sputum Clearance in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Acute exacerbation of COPD usually presents with more sputum production leading to worsening airflow obstruction. Often patients complain of sensation of sputum (phlegm) stuck in throat, which leads to worsening cough and…
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD Exacerbation, Airflow Obstruction
- Trial name
- NCT04217746
- Testing
- High Flow Nasal Cannula
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Tufts Medical Center
Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
Pulmonary arteriovenous malformations (PAVMs) are a rare vascular condition affecting the lungs. PAVMs lead to low blood oxygen levels, yet are very well tolerated by patients.
- Conditions
- Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia, Asthma, COPD
- Trial name
- ExercisePAVM2 (NCT02458703)
- Testing
- Cardiopulmonary exercise test
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Chronic Airflow Obstruction
A Study on Smoking-related Lung Function Abnormalities and Correlation With Serum Biomarkers in Chinese
Tobacco-smoking causes lung function decline with airflow obstruction, which may be accelerated in persistent smokers.This would eventually lead to chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and…
- Trial name
- NCT01185652
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- The University of Hong Kong
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-38 (NCT01045161)
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 544 people
- Sponsor
- AstraZeneca
Asthma, COPD
Undiagnosed COPD and Asthma Population Study (UCAP)
Previous population health studies suggest that up to 10% of Canadian adults have undiagnosed asthma or COPD- these people are currently undiagnosed and untreated, even though they may have significant respiratory symptoms.
- Trial name
- NCT03148210
- Testing
- Treatment strategy using evidence-based guidelines for asthma or COPD, Smoking Cessation, Participant Education
- Where
- 15 sites in Canada
- Volunteers
- 508 people
- Sponsor
- Ottawa Hospital Research Institute
Pulmonary Disease, Chronic Obstructive
Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or…
- Trial name
- NCT00671073
- Testing
- Oglemilast
- Where
- 47 sites in United States
- Volunteers
- 427 people
- Sponsor
- Forest Laboratories
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency
The Breathe NIOV™ System will reduce the work of breathing in subjects with chronic respiratory insufficiency who require long-term oxygen therapy (LTOT).
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- NCT01347931
- Testing
- NIOV System, Standard Oxygen Cannula
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Breathe Technologies, Inc.